Kalaris Therapeutics, Inc. (KLRS)
3.76
-0.28
(-6.93%)
USD |
NASDAQ |
Sep 01, 09:30
Kalaris Therapeutics Free Cash Flow : -45.63M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -45.63M |
| March 31, 2026 | -49.08M |
| December 31, 2025 | -43.18M |
| September 30, 2025 | -44.09M |
| June 30, 2025 | -36.90M |
| March 31, 2025 | -26.01M |
| December 31, 2024 | -23.09M |
| September 30, 2024 | -43.58M |
| June 30, 2024 | -73.72M |
| March 31, 2024 | -96.85M |
| December 31, 2023 | -124.45M |
| September 30, 2023 | -125.29M |
| June 30, 2023 | -125.94M |
| March 31, 2023 | -127.69M |
| Date | Value |
|---|---|
| December 31, 2022 | -142.05M |
| September 30, 2022 | -138.18M |
| June 30, 2022 | -139.52M |
| March 31, 2022 | -133.82M |
| December 31, 2021 | -106.34M |
| September 30, 2021 | -99.98M |
| June 30, 2021 | -81.56M |
| March 31, 2021 | -69.50M |
| December 31, 2020 | -61.05M |
| September 30, 2020 | -48.71M |
| June 30, 2020 | -37.05M |
| March 31, 2020 | -29.06M |
| December 31, 2019 | -20.49M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Replimune Group, Inc. | -280.54M |
| Arrowhead Pharmaceuticals, Inc. | -75.11M |
| Oncolytics Biotech, Inc. | -26.53M |
| Sangamo Therapeutics, Inc. | -90.46M |
| Sarepta Therapeutics, Inc. | 58.34M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -11.43M |
| Cash from Investing (Quarterly) | 20.17M |
| Cash from Financing (Quarterly) | 0.01M |
| Free Cash Flow Per Share (Quarterly) | -0.4804 |
| Free Cash Flow to Equity (Quarterly) | -11.42M |
| Free Cash Flow to Firm (Quarterly) | -11.43M |
| Free Cash Flow Yield | -54.47% |